Introduction {#S1}
============

KIT is a member of the tyrosine kinase-containing family of growth factor receptors which is expressed on restricted hematopoietic cell lineages including mast cells.([@R1]) Activation of KIT, following ligation by stem cell factor (SCF), is critical for mast cell growth, survival, differentiation and homeostasis and may contribute to mast cell homing to resident tissues.([@R2]) The extent of antigen-mediated mast cell activation within these tissues also has the capacity to be up regulated by SCF-dependent KIT activation.([@R3]) Hence inappropriate KIT activation profoundly influences mast cell-driven pathology.

Systemic mastocytosis is characterized by the pathologic accumulation of neoplastic mast cells in various tissues accompanied by activating mutations in KIT, most notably the aspartic acid to valine substitution at residue 816 (KIT D816V).([@R4]) Clinically, this clonal accumulation often results in persistent mast cell mediator-related symptoms and, in rare cases, aggressive neoplastic overgrowth with end organ failure. In these latter presentations, lifespan is significantly reduced and cytoreductive therapy is required.([@R5]) To date, tyrosine kinase inhibitors targeting the KIT D816V mutation have demonstrated only modest efficacy in advanced disease states and are often accompanied by significant side effects, likely the result of off-target kinase inhibition.([@R6]--[@R9])

Most tyrosine kinase inhibitors target the ATP binding pocket which is often conserved amongst kinases and subject to competition from high intracellular ATP concentrations. For reasons not clearly understood, certain ATP competitive inhibitors do not potently inhibit oncogenic forms of kinases which adopt aggressive, constitutively active conformations independent of normal regulatory mechanisms. KIT kinase can be aggressively activated in this manner and KIT mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.([@R10])

KIT has an interior pocket located between the N- and C-lobes of the kinase which functions as a switch pocket (SP). KIT also has two pendent switch ligands which compete for occupancy of this SP.([@R11]) If the inhibitory switch (exon 11 juxtamembrane domain) of KIT occupies this SP, the kinase adopts an inactive conformation. If the activating switch (exon 17 activation loop) occupies this SP, the kinase adopts a catalytically active conformation. Thus, changes in phosphorylation of both the inhibitory and activating switches govern the overall activity of KIT by regulation of the occupancy of its SP by its pendent inhibitory and activating switches.

Primary mutations and/or deletions in the exon 11 inhibitory switch render KIT constitutively active and such mutations drive the progression of gastrointestinal stromal tumors (GIST).([@R12]) In mast cell leukemia/mastocytosis, the primary KIT mutation resides in the activating switch, and in particular, the D816V exon 17 mutation is most aggressive. Classical ATP competitive KIT inhibitors, including imatinib, sunitinib, sorafenib, regorafenib, do not block this aggressive mutant form of KIT. The SP inhibitors, DP-2976 and DP-4851, were developed by rational design to block access to the KIT SP and prevent KIT D816V from adopting the catalytically active conformation. Additionally, because SP inhibitors are not ATP competitive, they are resilient even to high 4--5 mM concentrations of cellular ATP.

Here we describe the ability of two KIT SP inhibitors, DP-2976 and DP-4851, to potently and selectively inhibit both wild type (WT) and KIT D816V activation and consequently proliferation of both neoplastic and non-neoplastic mast cell populations. Furthermore, these inhibitors effectively blocked the ability of SCF to enhance antigen-mediated mast cell activation. These studies demonstrate that by targeting the switch pocket, this class of KIT inhibitors possesses a novel mechanism of inhibition whose dual suppression of KIT D816V neoplastic proliferation and SCF enhanced mast cell activation advocate future clinical development.

Patients, Materials and Methods {#S2}
===============================

Reagents and antibodies {#S3}
-----------------------

DP-2976 and DP-4851 were synthesized within Deciphera Pharmaceuticals LLC (Lawrence, KS, USA). PKC 412 and imatinib were purchased from LC laboratories (Woburn, MA, USA). All compounds were prepared and stored as a 10 mM stock solution in DMSO at −20°C. The following antibodies were used for immunoblotting: mouse anti human KIT (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti pKit (Tyr-823) (Invitrogen, Carlsbad, CA), anti β-- actin monoclonal antibody (Sigma-Aldrich, St. Louis, MO), horseradish peroxidase-conjugated anti-mouse (Sigma-Aldrich, St. Louis, MO) and anti-rabbit IgG (Amersham Biosciences, Piscataway, NJ).

In vitro kinase assays {#S4}
----------------------

KIT catalytic activity was determined by following the production of ADP from the kinase reaction through coupling with the pyruvate kinase/lactate dehydrogenase system.([@R13]) The reaction mixture (100 µl) contained KIT (KIT residues T544-V976, 6 nM), polyE4Y (1 mg/ml), MgCl~2~ (10 mM), pyruvate kinase (\~ 3 units), lactate dehydrogenase (\~ 4 units), phosphoenol pyruvate (1 mM), and NADH (0.28 mM) in 90 mM Tris buffer containing 0.2 % octyl-glucoside and 1% DMSO, pH 7.5. Test compounds were incubated with KIT and other reaction reagents at 30 °C for 30 min before ATP (0.2, 1.2 or 4 mM) was added to start the reaction. The absorption at 340 nm was monitored continuously for 1 h at 30°C. Percent inhibition was obtained by comparison of reaction rate with that of a control (i.e. with no test compound).

Cell culture {#S5}
------------

The HMC 1.1 and HMC 1.2 neoplastic mast cell lines were cultured as described.([@R14]) Both cell lines carry an activating KIT V560G mutation (loss-of-function mutation in the exon 11 inhibitory switch). In addition, the HMC 1.2 cell line harbors the KIT D816V mutation (gain-of-function mutation in the exon 17 activating switch). The 293T cell line was cultured in Iscove's DMEM containing 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (Mediatech, Manassas VA). Human mast cells (HuMCs) derived from CD34^+^ pluripotent blood progenitor cells were cultured as described.([@R15])

Cell transfections {#S6}
------------------

*pcDNA3-KIT* (GNNK+ variant([@R16])) was a kind gift from Gunnar Nilsson (Karolinska Institutet, Stockholm, Sweden). The *KIT D816V* mutation was created using the QuickChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions. *KIT* and *KIT D816V* open reading frames were cloned into the pcDNA3.1 expression vector (Invitrogen, Carlsbad, CA) using standard molecular biology techniques.([@R17]) These vectors were transfected into 293T cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. All transfections were carried out in DMEM medium containing 10% fetal bovine serum and 2 mM L-Glutamine. Three hundred thousand cells were plated in 6 well plates in 2 ml medium, and cultured overnight. The next day, the medium was replaced with 1 ml of fresh medium to which 1 µg of DNA and 5 µl of lipofectamine in 100 µl of Opti-MEM (Invitrogen, Carlsbad, CA) were added. Inhibitors (1 -- 1000 nM in a final concentration of 0.1% DMSO) were added to the indicated wells. After 24 h, cells were washed twice in PBS and lysed using 100 µl of RIPA buffer (Thermo Fisher, Pittsburgh, PA). The protein concentrations were measured using Bradford assay (Bio Rad, Hercules, CA) and 20 µg of protein were used for immunoblot analysis as described.([@R18]) Immunoreactive proteins were visualized with enhanced chemiluminesence (ECL) (Perkin Elmer Life Sciences, Waltham, MA) and the density of the appropriate bands was determined to quantitate the changes in phosphorylation.

Cell proliferation assay {#S7}
------------------------

HMC 1.1 and HMC 1.2 cells were plated at 5×10^4^ cells/mL with the inhibitors (1 -- 1000 nM) in a final concentration of 0.1% DMSO. After 72 h, an equal volume of 2X CyQuant direct detection reagent (Invitrogen) was added into the cells in culture. Following a 1 h incubation at 37°C with detection reagent, sample fluorescence was detected by using 492/535 nm wavelengths filter sets.

Apoptosis assay {#S8}
---------------

HMC 1.1 and HMC 1.2 cells were plated at 1×10^5^ cells/mL with 1000 nM of the inhibitors in DMSO (final concentration 0.1%). At 24, 48 and 72 h, annexin V staining using the Annexin V-FITC Apoptosis Detection Kit from BioVision (Mountain View, CA) was performed according to the manufacturer's instructions. The samples were analyzed using a FACSCalibur (BD Biosciences, San Jose, CA) flow cytometer equipped with Cellquest (BD Biosciences) software.

Human mast cell degranulation assay {#S9}
-----------------------------------

HuMCs were sensitized overnight with biotinylated-human IgE (100 ng/ml) in cytokine-free medium and rinsed with HEPES buffer (10 mM HEPES pH7.4, 137 mM NaCl, 27 mM KCl, 0.4 mM Na~2~HPO~4~.7H~2~O, 5.6 mM glucose, 1.8 mM CaCl~2~2H~2~O, 1.3 mM MgSO~4~.7H~2~O) containing 0.04% bovine serum albumin.([@R19]) Five thousand cells per well were plated in 96 well plates and preincubated in the presence and absence of inhibitors for 90 min at 37°C. The cells were then triggered with either 1 ng/ml streptavidin or 0.1 ng/ml streptavidin in the presence or absence of 10 ng/ml SCF. After 30 min, β--hexosaminidase (β-hex) activity in the supernatants and remaining cells was determined and degranulation was determined as the percentage of the total β-hex recovered from the supernatants.([@R20])

KIT phosphorylation {#S10}
-------------------

HuMCs were incubated overnight in growth medium without SCF and then washed 3 times in HEPES buffer containing 0.04% BSA. One million cells in 100 µl of HEPES buffer containing 0.04% BSA were pre-incubated with or without the inhibitors (1 -- 1000 nM in 0.1% DMSO) for 90 min at 37°C and then the cells were incubated with 10 ng/ml SCF for 2 min. Cell lysates were prepared and 20 µl aliquots were loaded on to 4 -- 12% NuPAGE Bis-Tris gels for electrophoretic separation and immunoblotting as described.([@R18]) Immunoreactive proteins were visualized with enhanced chemiluminesence ECL (Perkin Elmer Life Sciences, Waltham, MA) and the density of the appropriate bands was determined to quantitate the changes in phosphorylation.

HMC 1.1 and HMC 1.2 cells were incubated for 3 h in Iscove's DMEM media without FBS and then washed 3 times in HEPES buffer. Three hundred thousand cells in 100 µl of HEPES buffer containing 0.04% BSA were incubated with/without the inhibitors (1 -- 1000 nM in 0.1% DMSO) for 90 min at 37°C. Cell lysate preparation and immunoblotting was performed in the same manner as above.

Patient samples and *ex vivo* mast cell experiments {#S11}
---------------------------------------------------

Six patients with systemic mastocytosis were evaluated at the NIH between 2010 and 2011 as part of an Institutional Review Board-approved research protocol designed to study the pathogenesis and natural history of systemic mastocytosis (NCT00044122). All patients were diagnosed according to the World Health Organization (WHO) criteria.([@R5]) The presence of the *KIT D816V* mutation was determined by PCR/RFLP as described.([@R21]) Following informed consent, bone marrow mononuclear cells were isolated and incubated with the inhibitors (100, 1000 nM, 0.1% DMSO) for 7 d in the presence of SCF (100 ng/ml). Mast cell numbers were assessed by flow cytometry and normalized to numbers in the absence of inhibitor.([@R22])

Statistical analysis {#S12}
--------------------

Statistical analysis was performed using PRISM software, version 5 (GraphPad). Data were analyzed by a two tailed Student's *t* test. The levels of significance were as follows: \*, p\<0.05; \*\*, p\<0.005; \*\*\*, p\<0.0005. IC~50~ values were calculated using a nonlinear regression (curve fit)\--sigmoidal dose-response equation.

Results {#S13}
=======

DP-2976 and DP-4851 selectively inhibit WT and mutant KIT kinase activity at nanomolar concentrations {#S14}
-----------------------------------------------------------------------------------------------------

As part of drug discovery efforts, DP-2976 and DP-4851 were optimized for their inhibitory activity in KIT kinase assays. Low nanomolar IC~50~ values were observed in WT and mutated forms of KIT, including KIT D816V ([Figure 1A](#F1){ref-type="fig"}). The inhibitory potencies were unaffected by increases in ATP concentrations up to 4 mM ([Figure 1B](#F1){ref-type="fig"}), demonstrating that the ATP binding pocket was not targeted.

DP-2976 and DP-4851 inhibit intracellular KIT phosphorylation {#S15}
-------------------------------------------------------------

To explore the effects of the SP inhibitors on intracellular KIT activity, WT KIT and KIT D816V were expressed in 293T cells and the autophosphorylation status was assessed. Both DP-2976 and DP-4851 decreased the autophosphorylation of both wild type and KIT D816V in a concentration-dependent manner ([Figure 2](#F2){ref-type="fig"}).

The effect of the inhibitors on KIT phosphorylation was also examined in the HMC 1.1 (negative for D816V mutation) and HMC 1.2 (positive for D816V mutation) neoplastic human mast cell lines. DP-2976 and DP-4851 inhibited KIT phosphorylation in a dose dependent manner. Furthermore, these compounds appeared more potent than PKC 412 in this model ([Figure 3](#F3){ref-type="fig"}).

DP-2976 and DP-4851 inhibit growth and induce apoptosis in HMC-1.1 and HMC1.2 mast cell lines at nanomolar concentrations {#S16}
-------------------------------------------------------------------------------------------------------------------------

We next assessed the anti-neoplastic activity of the SP inhibitors in HMC 1.1 and HMC 1.2 cell proliferation assays. Both DP-2976 and DP-4851 potently inhibited HMC 1.1 proliferation with IC~50~ values of 2 nM and 4 nM respectively. These values were lower than that of imatinib (10 nM) or PKC 412 (135 nM) ([Figure 4A](#F4){ref-type="fig"}). Similarly, when evaluated in HMC 1.2 cells bearing the KIT D816V mutation, both DP-2976 and DP-4851 inhibited cell proliferation with IC~50~ values of 50 nM and 117 nM respectively. Similar to previous reports, imatinib demonstrated no activity and PKC 412 demonstrated an IC~50~ of 138 nM ([Figure 4B](#F4){ref-type="fig"}).([@R23])

The HMC 1.1 and HMC 1.2 cells were then treated with the inhibitors (1000 nM) and evaluated for apoptosis over 72 h. A time dependent increase in apoptosis was induced by the SP inhibitors in both cell lines, with over 60% of the cells annexin-V positive at the 72 h ([Figures 4C and 4D](#F4){ref-type="fig"}). Together, the SP inhibitors exhibited potent anti-neoplastic activity via apoptosis and outperformed current ATP competitive inhibitors in this system.

DP-2976 and DP-4851 inhibit survival of KIT D816V+ primary bone marrow mast cells {#S17}
---------------------------------------------------------------------------------

To determine if the *in vitro* observations translate clinically, we examined the efficacy of the SP inhibitors on neoplastic mast cells of patients with systemic mastocytosis. Patient characteristics are presented in [Table 1](#T1){ref-type="table"}. Patient ^\#^1 lacked the KIT D816V mutation and mast cells from this patient exhibited a dose dependent decrease in survival in response to the SP inhibitors ([Figure 5A](#F5){ref-type="fig"}). Furthermore, DP-2976 (1 µM) produced a 78% reduction (p\<0.0005) and DP-4851 a 63% reduction (p\<0.005) in the viability of mast cells collected from the bone marrow of KIT D816V-positive systemic mastocytosis patients (n=5) ([Figure 5B](#F5){ref-type="fig"}). A comparable level of reduction (88%) was seen with PKC 412 at 1000 nM (p\<0.0005). No statistical difference in inhibition profiles was observed in the absence of SCF (data not shown). These results support that targeting the KIT switch pocket offers an innovative mechanism of inhibition with potential clinical application.

DP-2976 and DP-4851 suppress KIT phosphorylation in primary human mast cells {#S18}
----------------------------------------------------------------------------

We next examined the effects of the inhibitors on WT KIT signaling in non-neoplastic HuMCs derived from peripheral blood progenitors, in response to SCF (10 ng/ml). In agreement with the transfection experiments (see [figure 2](#F2){ref-type="fig"}), both DP-2976 and DP-4851 inhibited KIT phosphorylation in a concentration-dependent manner ([Figure 6](#F6){ref-type="fig"}).

DP-2976 and DP-4851 inhibit SCF-enhanced mast cell activation {#S19}
-------------------------------------------------------------

In addition to the end organ damage induced by neoplastic mast cell proliferation, patients with systemic mastocytosis suffer from mast cell activation and mediator-related symptoms. Enhanced mast cell degranulation via KIT activation is well described and targeting such may provide therapeutic benefit. With this in mind we evaluated the SP inhibitors for their effect on SCF enhanced mast cell degranulation. DP-2976, DP-4851 and imatinib had minimal effects on FcεRI mediated mast cell degranulation ([Figure 7](#F7){ref-type="fig"}, open circles), with inhibition observed only at the highest concentration (1000 nM). SCF-enhanced degranulation ([Figure 7](#F7){ref-type="fig"}, solid circles) was evaluated in tandem and as previously observed, imatinib inhibited SCF-enhanced degranulation at the highest concentration (1000 nM).([@R19]) Additionally, both DP-2976 and DP-4851 also suppressed SCF-enhanced degranulation in a concentration-dependent manner with IC~50~ values of 18 nM and 27 nM respectively. In contrast, in addition to blocking SCF-enhanced degranulation (IC~50~=7nM), PKC 412 potently inhibited FcεRI-mediated degranulation (IC~50~=21nM). A similar reported observation suggested this to be the result of the inherent multi-kinase inhibition profile of PKC 412.([@R24])

Discussion {#S20}
==========

Targeting kinase control switch pockets appears a promising approach to effectively inhibit oncogenic kinase activity. Recently, DCC-2036 was identified as a switch pocket inhibitor of ABL kinase.([@R25], [@R26]) The gatekeeper mutant T315I represents an escape mutant of ABL and the oncogenic fusion protein BCR-ABL T315I is not readily controlled by currently marketed therapies.([@R27]) DCC-2036 potently blocks ABL T315I, signifying that SP inhibitors may hold promise to suppress other kinases harboring oncogenic mutations. Indeed, this study demonstrates that the KIT SP inhibitors, DP-2976 and DP-4851, effectively inhibit the KIT D816V activating mutation and offer a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation.

The inability of high ATP concentrations (4 mM) to blunt the inhibitory potencies of DP-2976 and DP-4851 further demonstrated that these KIT SP inhibitors function through an ATP-independent mechanism of action. Additionally, whereas ATP binding pockets are highly conserved throughout the kinome, switch pockets possess greater structural diversity. As a result, compounds targeting the switch pocket may inhibit kinase activity with higher selectivity. Indeed, the KIT SP inhibitors, DP-2976 and DP-4851, both displayed low nanomolar IC~50~ values in WT and KIT D816V kinase assays with modest off-target inhibition against other kinases (data not shown). Further, in our cell based assays, the KIT SP inhibitors displayed specific inhibition of KIT phosphorylation and KIT mediated (SCF) enhanced mast cell degranulation ([Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, [6](#F6){ref-type="fig"}, [7](#F7){ref-type="fig"}).

The ATP-competitive kinase inhibitor which has demonstrated the most promise for advanced forms of systemic mastocytosis is PKC 412.([@R28], [@R29]) PKC 412 is a multikinase inhibitor shown to not only inhibit neoplastic mast cell proliferation, but also antigen/IgE-dependent mediator release in human blood basophils and mast cells.([@R23], [@R24]) Both DP-2976 and DP-4851 exhibited more potent inhibition profiles compared to PKC 412 in the HMC 1.1 (KIT D816V negative) and HMC 1.2 (KIT D816V positive) neoplastic mast cell lines and induced similar levels of apoptosis ([Figure 4](#F4){ref-type="fig"}). *Ex vivo* studies examining the effects of the KIT SP inhibitors on neoplastic mast cells from patients with KIT D816V systemic mastocytosis displayed significant levels of inhibition comparable to PKC 412 ([Figure 5](#F5){ref-type="fig"}). Overall, DP-2976 and DP-4851 inhibited neoplastic mast cell proliferation and/or survival at a level similar to (if not greater) than PKC 412, which is currently in a phase II clinical trial for systemic mastocytosis.

As our molecular understanding of advanced forms of systemic mastocytosis evolves, it has become apparent that cooperating genetic events may account for the diverse phenotypes and variable therapeutic responses observed in the disease.([@R30]--[@R32]) Therefore, a multi-targeted therapeutic approach may be required.([@R33]) Whether the KIT SP inhibitors produce a synergistic effect when used in combination with kinase inhibitors targeting the ATP binding site or KIT independent targets is an area of further investigation. The selectivity of the KIT SP inhibitors should be advantageous in a combinational therapeutic approach.

In summary, we have demonstrated that targeting the switch pocket of KIT offers a novel and selective method to effectively suppress KIT D816V neoplastic proliferation and SCF enhanced mast cell activation. Our studies provide a strong rationale for further clinical development of KIT SP inhibitors for mastocytosis and other KIT driven disorders.
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![KIT SP inhibitors suppress WT and mutant KIT kinase activity at nanomolar concentrations via an ATP independent mechanism\
**A.** WT and mutant KIT kinase activity was measured in the presence of KIT SP inhibitors using the PK/LDH system. **B.** WT KIT kinase activity was measured in the presence of KIT SP inhibitors with varying concentrations (0.2, 1.2 or 4 mM) of ATP added to the reaction. IC~50~'s were calculated using the mean results of three separate experiments as shown for DP-2976 and DP-4851.](nihms396290f1){#F1}

![KIT SP inhibitors suppress KIT autophosphorylation in transfected 293T cells\
*KIT* and *KIT D816V* open reading frames were cloned into the pCDNA3.1 expression vector and transfected into 293T cells. The transfected cells were incubated with the KIT SP inhibitors (1 -- 1000 nM, 0.1% DMSO) for 24 h. The cells were lysed and used for immunoblot analysis. The blots are representative of three separate experiments. The graphs were generated by scanning the blots of the three separate experiments and then normalizing to the SCF untreated condition. Data are presented as means ± SEM.](nihms396290f2){#F2}

![KIT SP inhibitors suppress KIT autophosphorylation in HMC-1 mast cell lines\
HMC 1.1 and HMC 1.2 cells were incubated for 3 h in Iscove's DMEM media without FBS. The cells were washed 3 times in HEPES buffer containing 0.04% BSA. Three hundred thousand cells in 100 µl were then pre-incubated with the inhibitors (1 -- 1000 nM, 0.1% DMSO) for 90 min at 37°C and 20 µl of the cell lysate was used for immunoblot analysis. The blots are representative of three separate experiments.](nihms396290f3){#F3}

![KIT SP inhibitors suppress proliferation of, and induce apoptosis in, HMC-1 mast cell lines\
**A.** HMC 1.1 and **B.** HMC 1.2 cells were cultured in the presence of inhibitors (1 -- 1000 nM, 0.1% DMSO) for 72 h. A CyQuant cell proliferation assay was used to assess growth inhibition. Values represent the % viable cells as compared to untreated controls. The data are presented as means +/− SEM of three separate experiments each performed in triplicate. **C.** HMC 1.1 and **D**. HMC 1.2 cells were cultured in the presence of 1000 nM inhibitor. At various time points, the cells were double stained with annexin V-FITC and Sytox Green dye. Cells stained with annexin V were defined as apoptotic. Baseline values of annexin V positive cells in untreated cultures were subtracted from each treatment. The percent of apoptotic cells for each culture is plotted. The data are presented as the means ± SEM of three separate experiments, each performed in triplicate.](nihms396290f4){#F4}

![KIT SP inhibitors decrease the survival of primary bone marrow mast cells from patients with systemic mastocytosis\
Bone marrow mononuclear cells from patients with systemic mastocytosis **A.** without the KIT D816V mutation (n=1) or **B.** with the KIT D816V mutation (n=5) were isolated and incubated with the inhibitors (0, 100, 1000 nM in 0.1% DMSO) for 7 d in the presence of SCF (100 ng/ml). Mast cell numbers were assessed by flow cytometry and normalized to values in the absence of inhibitor. The data in B are presented as the mean ± SEM of results from five patients with KIT D816V systemic mastocytosis.](nihms396290f5){#F5}

![KIT SP inhibitors suppress KIT phosphorylation in primary HuMCs\
HuMCs were pre-incubated for 90 min with the inhibitors (1 -- 1000 nM, 0.1% DMSO). The cells were then stimulated with SCF (10 ng/ml) for 2 min, lysed and proteins separated by gel electrophoresis for immunoblot analysis. The blots are representative of three separate experiments. The graphs were generated by scanning the blots of the three separate experiments and then normalizing to the untreated condition. The data are presented as the mean ± SEM.](nihms396290f6){#F6}

![KIT SP inhibitors suppress SCF-enhanced degranulation of primary HuMCs\
HuMCs were sensitized overnight and pre-incubated with inhibitors for 90 min. Cells were then stimulated with ○ Ag (1 ng/ml) or ● Ag (0.1 ng/ml) +SCF (10 ng/ml) for 30 min. Degranulation was determined as % release of β-hexosaminidase. The data are presented as the mean ± SEM of three separate experiments each performed in triplicate.](nihms396290f7){#F7}

###### 

Characteristics of study subjects with Systemic Mastocytosis

  ---------------------------------------------------------------------------------------------------------------------
  Patient   WHO\             Age\      Gender   Serum\      Bone Marrow\   \% Mast Cell\     CD2/CD25\        *KIT*\
            Classification   (years)            Tryptase\   Mast Cell\     Involvement of\   Expression on\   *D816V*
                                                (ng/mL)     Aggregates     Bone Marrow       Mast Cells       
  --------- ---------------- --------- -------- ----------- -------------- ----------------- ---------------- ---------
  1         Indolent         67        F        27          \+             10                −                −

  2         Indolent         65        F        118         \+             10--15            \+               \+

  3         Indolent         24        F        10          −              \<5               \+               \+

  4         Indolent         24        F        80          \+             10--15            \+               \+

  5         Smoldering       55        F        119         \+             20--30            \+               \+

  6         Smoldering       48        F        166         \+             50                \+               \+
  ---------------------------------------------------------------------------------------------------------------------
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